MAR 17, 2016 10:30 AM PDT

Promise and challenges of iPSC modeling in Parkinson's disease

Speaker
  • Associate Professor, Program Director of Gene Discovery and Stem Cell Modeling Parkinson's Institute and Clinical Center
    BIOGRAPHY

Abstract

Given the challenges of replicating Parkinson’s disease in animal models, returning to models that are human-based and highly clinically characterized may provide the most successful path forward. There is a critical need to differentiate Lewy body Parkinson’s disease from other non-Lewy body forms of parkinsonism. This is important because the underlying molecular pathomechanisms, and hence potential therapeutic targets, are unlikely to be similar for both.
One exciting new avenue regarding modeling human disease is the use of induced pluripotent stem cell (iPSC) technology utilizing individual donors with clear clinical diagnosis of disease. In regard to modeling Lewy body Parkinson’s disease, patient-specific iPSCs lay the foundation for differentiation into the tissue-type of interest, i.e. mid-brain dopaminergic neurons. Using such a collection of iPSCs that is thoroughly characterized with high-quality and comprehensive clinical data and eventually with confirmative neuropathology at autopsy is the key for successful interpretation of findings.
 
However, in order for iPSC modeling approach to produce validated results, several challenges must be addressed to reduce variability of intrinsic and extrinsic nature. This is why it is critical that the methods used to generate iPSCs are documented and performed in a consistent manner to minimize variability. Another critical area for improvement is the use of consistent (or at least well documented) methods for differentiation of these patient-derived iPSC lines into neuronal cultures. The field is in dire need of standardized and validated iPS laboratory practices to generate and characterize cells and phenotypes of interest to understand disease and to identify new targets.
 
Learning objectives:
•           Clinical and pathological characterization of Lewy body Parkinson’s disease
•           Critical factors of intrinsic and extrinsic variability for iPS cell modeling
 


Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 11, 2022 8:00 AM PDT
C.E. CREDITS
OCT 11, 2022 8:00 AM PDT
Date: October 11, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Multiomic profiling of cell populations at single-cell resolution is revolutionizing scientists’ understanding o...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
MAR 17, 2016 10:30 AM PDT

Promise and challenges of iPSC modeling in Parkinson's disease



Show Resources
Loading Comments...
Show Resources
Attendees